[Use of Bisphosphonates in Orthopedic Surgery]

Overview

Journal Orthopade

Specialty Orthopedics

Date 2008 Jun 6

PMID 18528681

Citations 6

Authors

R Bartl

C Bartl

R Gradinger

Affiliations

Soon will be listed here.

Abstract

Over the past three decades, the members of the substance group called bisphosphonates (BP) have been employed with growing success to manage osteopathies caused by increased osteoclastic activity. The following developments in BP are responsible: Modern BP are now already 20,000 times more potent than the first preparation approved for use. Their biochemical and cellular mechanisms of action have meanwhile been elucidated. They have no effect on hormones so that they are open for all patients. They are well tolerated and can be administered orally or intravenously. They have admirably been thoroughly studied in multinational trials. They are the "gold standard" in the treatment of osteoporosis, a widespread disease. Rare but serious side effects such as osteonecrosis of the jaw or acute renal insufficiency can be avoided to a large extent. BP also have tumoricidal properties and are used to suppress tumor growth in bones. Their anti-inflammatory activity is also successfully used in the treatment of bone marrow edema and bone pain.

Citing Articles

Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.

He Y, Xu W, Xiao Y, Huang H, Gu D, Ren S Signal Transduct Target Ther. 2022; 7(1):198.

PMID: 35750683 PMC: 9232569. DOI: 10.1038/s41392-022-01042-7.

Clinical course in two children with Juvenile Paget's disease during long-term treatment with intravenous bisphosphonates.

Hoppner J, Steff K, Misof B, Schundeln M, Hovel M, Lucke T Bone Rep. 2021; 14:100762.

PMID: 33850973 PMC: 8039828. DOI: 10.1016/j.bonr.2021.100762.

Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.

Jakob T, Tesfamariam Y, Macherey S, Kuhr K, Adams A, Monsef I Cochrane Database Syst Rev. 2020; 12:CD013020.

PMID: 33270906 PMC: 8095056. DOI: 10.1002/14651858.CD013020.pub2.

Bisphosphonates for advanced prostate cancer.

Macherey S, Monsef I, Jahn F, Jordan K, Yuen K, Heidenreich A Cochrane Database Syst Rev. 2017; 12:CD006250.

PMID: 29278410 PMC: 6486306. DOI: 10.1002/14651858.CD006250.pub2.

The effect of vitamin D and bisphosphonate on fracture healing: An experimental study.

Aydogan N, Ozel I, Iltar S, Kara T, Ozmeric A, Alemdaroglu K J Clin Orthop Trauma. 2016; 7(2):90-4.

PMID: 27182145 PMC: 4857164. DOI: 10.1016/j.jcot.2016.01.003.

References

Body J, Bartl R, Burckhardt P, Delmas P, Diel I, Fleisch H . Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol. 1998; 16(12):3890-9. DOI: 10.1200/JCO.1998.16.12.3890. View

Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen H . Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001; 19(2):558-67. DOI: 10.1200/JCO.2001.19.2.558. View

Kanis J, Burlet N, Cooper C, Delmas P, Reginster J, Borgstrom F . European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008; 19(4):399-428. PMC: 2613968. DOI: 10.1007/s00198-008-0560-z. View

Wang C, Wang J, Weng L, Hsu C, Huang C, Chen H . The effect of alendronate on bone mineral density in the distal part of the femur and proximal part of the tibia after total knee arthroplasty. J Bone Joint Surg Am. 2003; 85(11):2121-6. DOI: 10.2106/00004623-200311000-00009. View

Sundfeldt M, Carlsson L, Johansson C, Thomsen P, Gretzer C . Aseptic loosening, not only a question of wear: a review of different theories. Acta Orthop. 2006; 77(2):177-97. DOI: 10.1080/17453670610045902. View

Tanzer M, Karabasz D, Krygier J, Cohen R, Bobyn J . The Otto Aufranc Award: bone augmentation around and within porous implants by local bisphosphonate elution. Clin Orthop Relat Res. 2005; 441:30-9. DOI: 10.1097/01.blo.0000194728.62996.2d. View

Hilding M, Aspenberg P . Local peroperative treatment with a bisphosphonate improves the fixation of total knee prostheses: a randomized, double-blind radiostereometric study of 50 patients. Acta Orthop. 2008; 78(6):795-9. DOI: 10.1080/17453670710014572. View

Lee Y, Low S, Lim L, Loke K . Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr. 2002; 160(11):641-4. DOI: 10.1007/s004310100844. View

Reid I, Miller P, Lyles K, Fraser W, Brown J, Saidi Y . Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med. 2005; 353(9):898-908. DOI: 10.1056/NEJMoa044241. View

10.

Teitelbaum S . Bone resorption by osteoclasts. Science. 2000; 289(5484):1504-8. DOI: 10.1126/science.289.5484.1504. View

11.

Mont M, Jones L, Hungerford D . Nontraumatic osteonecrosis of the femoral head: ten years later. J Bone Joint Surg Am. 2006; 88(5):1117-32. DOI: 10.2106/JBJS.E.01041. View

12.

Kock F, Borisch N, Koester B, Grifka J . [Complex regional pain syndrome type I (CRPS I). Pathophysiology, diagnostics, and therapy]. Orthopade. 2003; 32(5):418-31. DOI: 10.1007/s00132-003-0468-4. View

13.

Bhandari M, Bajammal S, Guyatt G, Griffith L, Busse J, Schunemann H . Effect of bisphosphonates on periprosthetic bone mineral density after total joint arthroplasty. A meta-analysis. J Bone Joint Surg Am. 2005; 87(2):293-301. DOI: 10.2106/JBJS.D.01772. View

14.

Bartl R . [Practical guidelines for the management of osteoporosis--evidence-based and cost-effective]. Dtsch Med Wochenschr. 2007; 132(18):995-9. DOI: 10.1055/s-2007-979369. View

15.

Schott G . Bisphosphonates for pain relief in reflex sympathetic dystrophy?. Lancet. 1997; 350(9085):1117. DOI: 10.1016/s0140-6736(05)63785-3. View

16.

Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J . Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809-22. DOI: 10.1056/NEJMoa067312. View

17.

Cao Y, Mori S, Mashiba T, Westmore M, Ma L, Sato M . Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res. 2002; 17(12):2237-46. DOI: 10.1359/jbmr.2002.17.12.2237. View

18.

Little D, Cornell M, Briody J, Cowell C, Arbuckle S . Intravenous pamidronate reduces osteoporosis and improves formation of the regenerate during distraction osteogenesis. A study in immature rabbits. J Bone Joint Surg Br. 2001; 83(7):1069-74. DOI: 10.1302/0301-620x.83b7.10542. View

19.

Marini J . Do bisphosphonates make children's bones better or brittle?. N Engl J Med. 2003; 349(5):423-6. DOI: 10.1056/NEJMp038103. View

20.

Morris C, Einhorn T . Bisphosphonates in orthopaedic surgery. J Bone Joint Surg Am. 2005; 87(7):1609-18. DOI: 10.2106/JBJS.D.03032. View